Guangzhou Saijun Biotechnology Co., Ltd. has recently made public the successful conclusion of its Pre-C round funding, which has surpassed RMB 100 million. This significant funding round was co-led by the Shenzhen Hetao Healthcare Sub-Fund, under the auspices of the Taiping Healthcare Fund, and the Yuecai Zhongyin Fund. Additional financial support was provided by Songhe Capital, an existing shareholder. The proceeds from this funding will be primarily allocated towards accelerating the clinical development of its key product pipelines, establishing a robust commercialization team, expanding market reach, and conducting pre-clinical research and development for innovative product lines. As a leading entity in stem cell research and its commercial application, Saijun Biotechnology stands out with over a decade's worth of scientific research achievements. The company has made remarkable strides in the development of its core product pipelines and clinical data, while also enjoying a pioneering edge in its commercialization strategy.